Early proactive monitoring of DNA-thioguanine in patients with Crohn’s disease predicts thiopurine-induced late leucopenia in NUDT15/TPMT normal metabolizers

Figure 7 The cumulative events of leucopenia with corresponding DNA-thioguanine thresholds in the entire and thiopurine methyltransferase/nudix hydrolase 15 wild-type populations. A: Cumulative incidence rates were significantly greater in patients with DNA-thioguanine (DNATG) concentrations of more than 319.43 fmol/μg DNA in the entire population; B: Cumulative incidence rates were significantly greater in patients with DNATG concentrations of more than 315.72 fmol/μg DNA in the thiopurine methyltransferase/nudix hydrolase 15 wild-type population. Both log-rank P < 0.001. Kaplan-Meier survival analysis followed by the log-rank test was employed to estimate cumulative leucopenia events.